Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLS001
MIFTS: 58

Gliosarcoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gliosarcoma

About this section

MalaCards integrated aliases for Gliosarcoma:

Name: Gliosarcoma 12 76 53 59 55 44 15 73
Glioblastoma with Sarcomatous Component 12
Sarcomatous Glioblastoma 53

Characteristics:

Orphanet epidemiological data:

59
gliosarcoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3071
MeSH 44 D018316
NCIt 50 C3796
SNOMED-CT 68 35262004
Orphanet 59 ORPHA251576
ICD10 via Orphanet 34 G71.9
UMLS via Orphanet 74 C0206726
UMLS 73 C0206726
Sources

Summaries for Gliosarcoma

About this section
MalaCards based summary : Gliosarcoma, also known as glioblastoma with sarcomatous component, is related to glioma susceptibility 1 and glioblastoma, and has symptoms including seizures and headache. An important gene associated with Gliosarcoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Procarbazine and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and prostate, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Gliosarcoma is a rare type of glioma, a cancer of the brain that comes from glial, or supportive, brain... more...

Sources

Related Diseases for Gliosarcoma

About this section

Diseases related to Gliosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 30.8 GFAP IDH1 PPARG TP53
2 glioblastoma 30.8 EGFR FGFR1 IDH1 MGMT PPARG PTEN
3 ependymoma 30.5 EGFR GFAP MGMT NES
4 glioblastoma multiforme 30.4 EGFR GFAP IDH1 MGMT NES PPARG
5 grade iii astrocytoma 30.4 EGFR GFAP MGMT PTEN TP53
6 oligodendroglioma 30.3 EGFR GFAP IDH1 MGMT PTEN TP53
7 anaplastic ganglioglioma 30.3 GFAP NES
8 ganglioglioma 30.3 GFAP NES TP53
9 teratoma 30.2 GFAP NES TP53
10 glioma 30.2 EGFR FGFR1 IDH1 PPARG PTEN TP53
11 fibrillary astrocytoma 30.2 GFAP IDH1 MGMT TP53
12 li-fraumeni syndrome 30.0 EGFR IDH1 PTEN TP53
13 medulloblastoma 29.9 EGFR FGFR1 GFAP IDH1 MGMT NES
14 giant cell glioblastoma 29.1 EGFR FGFR1 FGFR3 GFAP IDH1 LZTR1
15 adult brainstem gliosarcoma 12.2
16 frontal convexity meningioma 10.4 GFAP TP53
17 gliofibroma 10.4 GFAP TP53
18 oligoastrocytoma 10.4 GFAP MGMT
19 central nervous system primitive neuroectodermal neoplasm 10.4 GFAP NES TP53
20 ependymoblastoma 10.4 GFAP NES TP53
21 brain ependymoma 10.3 EGFR TP53
22 cerebral convexity meningioma 10.3 GFAP TP53
23 optic nerve glioma 10.3 GFAP NES TP53
24 cellular ependymoma 10.3 GFAP TP53
25 anaplastic oligodendroglioma 10.3 EGFR GFAP MGMT
26 protoplasmic astrocytoma 10.3 GFAP TP53
27 extraventricular neurocytoma 10.3 GFAP IDH1
28 splenic diffuse red pulp small b-cell lymphoma 10.3 CCND3 TP53
29 intracranial chondrosarcoma 10.3 IDH1 TP53
30 nervous system benign neoplasm 10.3 GFAP LZTR1 TP53
31 mixed glioma 10.3 GFAP IDH1 TP53
32 non-invasive bladder papillary urothelial neoplasm 10.3 FGFR3 TP53
33 cerebellar astrocytoma 10.3 IDH1 TP53
34 adult medulloblastoma 10.3 GFAP IDH1 TP53
35 benign glioma 10.3 GFAP PPARG TP53
36 dysembryoplastic neuroepithelial tumor 10.3 GFAP IDH1 NES
37 plagiocephaly 10.3 FGFR1 FGFR3
38 actinic cheilitis 10.3 FGFR3 TP53
39 breast carcinoma in situ 10.3 EGFR FGFR1 TP53
40 adult oligodendroglioma 10.3 FGFR1 IDH1
41 osteochondroma 10.3 FGFR1 FGFR3 NES
42 pleomorphic xanthoastrocytoma 10.3 GFAP IDH1 MGMT TP53
43 spinal cord astrocytoma 10.3 GFAP IDH1 MGMT TP53
44 central nervous system germ cell tumor 10.3 GFAP NES
45 gemistocytic astrocytoma 10.2 GFAP PTEN
46 meninges sarcoma 10.2 GFAP TP53
47 small cell carcinoma 10.2 EGFR PTEN TP53
48 intrahepatic cholangiocarcinoma 10.2 EGFR IDH1 TP53
49 chromosome 2q35 duplication syndrome 10.2 FGFR3 FREM2 PIK3R2
50 chordoma 10.2 EGFR GFAP PTEN

Graphical network of the top 20 diseases related to Gliosarcoma:



Diseases related to Gliosarcoma
Sources

Symptoms & Phenotypes for Gliosarcoma

About this section

UMLS symptoms related to Gliosarcoma:


seizures, headache

GenomeRNAi Phenotypes related to Gliosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.66 EGFR
2 Decreased viability GR00173-A 9.66 PIK3R2
3 Decreased viability GR00221-A-1 9.66 EGFR FGFR1 FGFR3 PIK3R2 PPARG
4 Decreased viability GR00221-A-2 9.66 FGFR1 FGFR3 PIK3R2 PPARG
5 Decreased viability GR00221-A-3 9.66 FGFR3 PPARG
6 Decreased viability GR00221-A-4 9.66 EGFR PIK3R2 PPARG
7 Decreased viability GR00301-A 9.66 PIK3R2
8 Decreased viability GR00402-S-2 9.66 EGFR FGFR1 FGFR3 PIK3R2 PPARG

MGI Mouse Phenotypes related to Gliosarcoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 CCND3 EGFR FGFR1 FGFR3 FREM2 GFAP
2 homeostasis/metabolism MP:0005376 10.37 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1
3 mortality/aging MP:0010768 10.33 CCND3 EGFR FGFR1 FGFR3 FREM2 GFAP
4 hematopoietic system MP:0005397 10.31 CCND3 EGFR FGFR1 FGFR3 IDH1 LZTR1
5 cardiovascular system MP:0005385 10.3 CCND3 EGFR FGFR1 FREM2 GFAP PIK3R2
6 immune system MP:0005387 10.29 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1
7 endocrine/exocrine gland MP:0005379 10.27 CCND3 EGFR FGFR1 MGMT NFKBIA PPARG
8 embryo MP:0005380 10.18 EGFR FGFR1 FREM2 PPARG PTEN SNAI2
9 integument MP:0010771 10.15 EGFR FGFR1 FGFR3 FREM2 NFKBIA PPARG
10 craniofacial MP:0005382 10.14 EGFR FGFR1 FGFR3 FREM2 SNAI2 TACC3
11 digestive/alimentary MP:0005381 10.13 EGFR FGFR1 FGFR3 GFAP PTEN SNAI2
12 normal MP:0002873 10.07 CCND3 EGFR FGFR1 FGFR3 GFAP NFKBIA
13 neoplasm MP:0002006 10.06 CCND3 EGFR FGFR3 MGMT PIK3R2 PPARG
14 muscle MP:0005369 10.03 EGFR FGFR1 FREM2 GFAP PIK3R2 PPARG
15 hearing/vestibular/ear MP:0005377 10.02 EGFR FGFR1 FGFR3 FREM2 PPARG TP53
16 limbs/digits/tail MP:0005371 10.02 EGFR FGFR1 FGFR3 FREM2 PTEN TACC3
17 renal/urinary system MP:0005367 9.8 EGFR FGFR1 FGFR3 FREM2 PPARG PTEN
18 respiratory system MP:0005388 9.76 CCND3 EGFR FGFR3 FREM2 IDH1 MGMT
19 pigmentation MP:0001186 9.72 EGFR FREM2 PTEN SNAI2 TP53
20 skeleton MP:0005390 9.65 EGFR FGFR1 FGFR3 FREM2 IDH1 PPARG
21 vision/eye MP:0005391 9.32 CCND3 EGFR FGFR1 FGFR3 FREM2 GFAP
Sources

Drugs & Therapeutics for Gliosarcoma

About this section

Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 405)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Procarbazine Approved, Investigational Phase 3,Phase 1,Phase 2 671-16-9 4915
2
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
3
Lomustine Approved, Investigational Phase 3,Phase 1 13010-47-4 3950
4
Trioxsalen Approved Phase 3,Phase 1 3902-71-4 5585
5
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
6
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
9
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
10
Vincristine Approved, Investigational Phase 3,Phase 1,Phase 2 57-22-7, 2068-78-2 5978
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
13
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
14
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
15
Dopamine Approved Phase 3,Phase 1,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
16
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
19 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
20
Veliparib Investigational Phase 2, Phase 3,Phase 1 912444-00-9 11960529
21 Dianhydrogalactitol Investigational Phase 3 23261-20-3
22 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
24 Ether Phase 3
25 Photosensitizing Agents Phase 3,Phase 2,Phase 1
26 Dihematoporphyrin Ether Phase 3,Phase 1
27 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2,Early Phase 1
30 Antibodies Phase 3,Phase 1,Phase 2,Early Phase 1
31 Immunoglobulins Phase 3,Phase 1,Phase 2,Early Phase 1
32 Immunologic Factors Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
33 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Not Applicable
35 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
36 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antimitotic Agents Phase 3,Phase 1,Phase 2
39 Keratolytic Agents Phase 3,Phase 1,Phase 2
40 O(6)-benzylguanine Phase 3,Phase 2,Phase 1,Not Applicable
41 Immunoglobulin G Phase 3,Phase 2,Phase 1
42 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
43 Mitogens Phase 3,Phase 2,Phase 1
44 Anesthetics, General Phase 3
45 Hematoporphyrin Derivative Phase 3
46 Hematoporphyrins Phase 3
47 Anesthetics, Inhalation Phase 3
48 Anesthetics Phase 3,Phase 1
49 Cola Phase 3,Phase 1
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 471)
# Name Status NCT ID Phase Drugs
1 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
2 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
3 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
4 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
5 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
6 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
7 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
8 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
9 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
10 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
11 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
12 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
13 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
16 A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Recruiting NCT02573324 Phase 3 Temozolomide;ABT-414;Placebo for ABT-414
17 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Active, not recruiting NCT02152982 Phase 2, Phase 3 Temozolomide;Veliparib
18 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Active, not recruiting NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
19 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
21 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
22 Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma Unknown status NCT01124539 Phase 2 AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
23 Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 Unknown status NCT02430363 Phase 1, Phase 2 MK - 3475
24 Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Unknown status NCT01013285 Phase 2 temozolomide
25 Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma Unknown status NCT00936052 Phase 2
26 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
27 Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00486603 Phase 1, Phase 2 hydroxychloroquine;temozolomide
28 Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
29 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
30 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
31 Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2 carboplatin;temozolomide
32 Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
33 Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2 carmustine in ethanol
34 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
35 Bevacizumab in Recurrent Grade II and III Glioma Unknown status NCT01164189 Phase 2 Temozolomide
36 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
37 Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma Completed NCT00525525 Phase 2 Bevacizumab;Tarceva;Temozolomide
38 Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas Completed NCT00612339 Phase 2 Avastin and Temozolomide
39 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2 sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
40 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Completed NCT00597402 Phase 2 Avastin;Temozolomide;Irinotecan
41 Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Completed NCT00402116 Phase 1, Phase 2 enzastaurin;temozolomide
42 Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors Completed NCT00187486 Phase 2 Tarceva;Temodar
43 Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed NCT00305864 Phase 1, Phase 2 Motexafin Gadolinium;Temozolomide
44 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed NCT00433381 Phase 2 Irinotecan Hydrochloride;Temozolomide
45 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Completed NCT00979017 Phase 2 Avastin;Temozolomide;Irinotecan
46 Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed NCT00720356 Phase 2 bevacizumab;erlotinib hydrochloride
47 Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00423735 Phase 2 Dasatinib
48 Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00165477 Phase 2 lenalidomide
49 Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Completed NCT00883298 Phase 2 temozolomide and bevacizumab
50 AMG 102 and Avastin for Recurrent Malignant Glioma Completed NCT01113398 Phase 2 AMG 102;Avastin

Search NIH Clinical Center for Gliosarcoma

Cochrane evidence based reviews: gliosarcoma

Sources

Genetic Tests for Gliosarcoma

About this section
Sources

Anatomical Context for Gliosarcoma

About this section

MalaCards organs/tissues related to Gliosarcoma:

41
Brain, T Cells, Prostate, Spinal Cord, Bone, Pineal, Endothelial
Sources

Publications for Gliosarcoma

About this section

Articles related to Gliosarcoma:

(show top 50) (show all 383)
# Title Authors Year
1
Gliosarcoma: a clinical and radiological analysis of 48 cases. ( 29948068 )
2018
2
Treatment-associated<i>TP53</i>DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma. ( 29416795 )
2018
3
Adjuvant Radiation Therapy and Temozolomide in Gliosarcoma: Is It Enough? Case Series of Seven Patients. ( 29682024 )
2018
4
Giant parieto-occipital lobe pediatric gliosarcoma: Report of a rare entity and review of literature. ( 29930877 )
2018
5
Pineal gliosarcoma in a 5-year-old girl. ( 29487662 )
2018
6
Gliosarcoma with primitive neuronal, chondroid, osteoid and ependymal elements. ( 29504169 )
2018
7
Biological characteristics and outcomes of Gliosarcoma. ( 30108403 )
2018
8
Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses. ( 30246385 )
2018
9
Gliosarcoma: Neuroimaging and Immunohistochemical Findings. ( 30295979 )
2018
10
Gliosarcoma of Cerebello-Pontine Angle: A Case Report and Review of the Literature. ( 30381921 )
2018
11
Gliosarcoma with long progression free survival: A case report and literature review. ( 30533274 )
2018
12
Photodithazine photodynamic effect on viability of 9L/lacZ gliosarcoma cell line. ( 28503718 )
2017
13
Reproducibility and relative stability in magnetic resonance imaging indices of tumor vascular physiology over a period of 24h in a rat 9L gliosarcoma model. ( 28887206 )
2017
14
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted. ( 28812310 )
2017
15
Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case. ( 28261869 )
2017
16
Lateral ventricular gliosarcoma with attachment to septum pellucidum. ( 28413542 )
2017
17
Glioblastoma recurrence, progression, and dissemination as a purely subdural gliosarcoma. ( 28290000 )
2017
18
Analysis of outcomes of multidisciplinary management of Gliosarcoma: a single centre study, 2000-2013. ( 28642179 )
2017
19
Detailed magnetic resonance imaging features of a case series of primary gliosarcoma. ( 28644110 )
2017
20
The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients? ( 29045711 )
2017
21
Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. ( 28621623 )
2017
22
Primary gliosarcoma: epidemiology, clinical presentation, management and survival. ( 29154508 )
2017
23
Gliosarcoma in septuagenarians and octogenarians: What is the impact of adjuvant chemoradiation? ( 28756069 )
2017
24
Functional and morphological effects of diazepam and midazolam on tumor vasculature in the 9L gliosarcoma brain tumor model using dynamic susceptibility contrast MRI: a comparative study. ( 29042753 )
2017
25
Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. ( 29264835 )
2017
26
Gliosarcoma in Young Adults: A Rare Variant of Glioblastoma. ( 29147435 )
2017
27
High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. ( 28408749 )
2017
28
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )
2016
29
Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. ( 26725096 )
2016
30
Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. ( 27169763 )
2016
31
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27314913 )
2016
32
An IDH1-mutated primary gliosarcoma: case report. ( 27153165 )
2016
33
Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and clinical tissue imaging. ( 26802746 )
2016
34
Radiotherapy plus concomitant temozolomide in primary gliosarcoma. ( 27025857 )
2016
35
Dural and osteolytic sarcomatoid relapse of a secondary gliosarcoma with tryptase immunoreactivity. ( 26784965 )
2016
36
A Stable Secondary Gliosarcoma with Extensive Systemic Metastases: A Case Report. ( 27867925 )
2016
37
Temporal Lobe Gliosarcoma After Gamma Knife Radiosurgery for Vestibular Schwannoma. ( 27309712 )
2016
38
Gliosarcoma with Primary Skull Base Invasion. ( 28053799 )
2016
39
Gliosarcoma with a primitive neuroectodermal tumour component. ( 27772848 )
2016
40
Metastatic Gliosarcoma: Cytopathologic Characteristics with Histopathologic Correlations. ( 27584833 )
2016
41
Gliosarcoma with smooth muscle cell differentiation: a case report. ( 27704522 )
2016
42
Gliosarcoma: A rare variant of glioblastoma multiforme in paediatric patient: Case report and review of literature. ( 27672648 )
2016
43
Primary Multifocal Gliosarcoma of the Spinal Cord. ( 27134708 )
2016
44
Evaluation of Antitumor Activity of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid in Animal Models of Breast Tumor and Gliosarcoma. ( 27130721 )
2016
45
Gliosarcoma in the Cerebellopontine Angle with Rapid Tumor Growth and Intratumoral Hemorrhage. ( 27338213 )
2016
46
Concurrent Gliosarcoma and Choroid Plexus Carcinoma in a Cow. ( 27899174 )
2016
47
Post-Treatment Gliosarcoma Extension into the Pterygomaxillary Fossa: Literature Review and Case Report. ( 27699141 )
2016
48
Primary Gliosarcoma of the Optic Nerve: A Unique Adult Optic Pathway Glioma. ( 27792048 )
2016
49
Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a gliosarcoma patient. ( 27523101 )
2016
50
Assessing Amide Proton Transfer (APT) MRI Contrast Origins in 9A L Gliosarcoma in the Rat Brain Using Proteomic Analysis. ( 25622812 )
2015
Sources

Variations for Gliosarcoma

About this section

Cosmic variations for Gliosarcoma:

9 (show top 50) (show all 75)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10704 TP53 central nervous system,brain,glioma,gliosarcoma c.844C>T p.R282W 17:7673776-7673776 6
2 COSM10656 TP53 central nervous system,brain,glioma,gliosarcoma c.742C>T p.R248W 17:7674221-7674221 6
3 COSM10893 TP53 central nervous system,brain,glioma,gliosarcoma c.824G>A p.C275Y 17:7673796-7673796 6
4 COSM10648 TP53 central nervous system,brain,glioma,gliosarcoma c.524G>A p.R175H 17:7675088-7675088 6
5 COSM11244 TP53 central nervous system,brain,glioma,gliosarcoma c.764T>A p.I255N 17:7674199-7674199 6
6 COSM44171 TP53 central nervous system,brain,glioma,gliosarcoma c.840A>T p.R280S 17:7673780-7673780 6
7 COSM10742 TP53 central nervous system,brain,glioma,gliosarcoma c.578A>G p.H193R 17:7674953-7674953 6
8 COSM6914505 STAG2 central nervous system,brain,glioma,gliosarcoma c.953T>G p.M318R 23:124050245-124050245 6
9 COSM6914502 SMAD3 central nervous system,brain,glioma,gliosarcoma c.686C>T p.P229L 15:67181268-67181268 6
10 COSM6914501 RB1 central nervous system,brain,glioma,gliosarcoma c.446C>A p.S149* 13:48345145-48345145 6
11 COSM866 RB1 central nervous system,brain,glioma,gliosarcoma c.1399C>T p.R467* 13:48380062-48380062 6
12 COSM24612 PTPN11 central nervous system,brain,glioma,gliosarcoma c.922A>G p.N308D 12:112477719-112477719 6
13 COSM5308 PTEN central nervous system,brain,glioma,gliosarcoma c.565A>T p.R189* 10:87952190-87952190 6
14 COSM5089 PTEN central nervous system,brain,glioma,gliosarcoma c.517C>T p.R173C 10:87952142-87952142 6
15 COSM13731 PTEN central nervous system,brain,glioma,gliosarcoma c.802-2A>T p.? 10:87960892-87960892 6
16 COSM5154 PTEN central nervous system,brain,glioma,gliosarcoma c.697C>T p.R233* 10:87957915-87957915 6
17 COSM5191 PTEN central nervous system,brain,glioma,gliosarcoma c.198G>T p.K66N 10:87925546-87925546 6
18 COSM5152 PTEN central nervous system,brain,glioma,gliosarcoma c.388C>T p.R130* 10:87933147-87933147 6
19 COSM6954363 PTEN central nervous system,brain,glioma,gliosarcoma c.688G>T p.G230* 10:87957906-87957906 6
20 COSM5033 PTEN central nervous system,brain,glioma,gliosarcoma c.389G>A p.R130Q 10:87933148-87933148 6
21 COSM5123 PTEN central nervous system,brain,glioma,gliosarcoma c.395G>A p.G132D 10:87933154-87933154 6
22 COSM6955728 PTEN central nervous system,brain,glioma,gliosarcoma c.686C>A p.S229* 10:87957904-87957904 6
23 COSM5162 PTEN central nervous system,brain,glioma,gliosarcoma c.821G>A p.W274* 10:87960913-87960913 6
24 COSM775 PIK3CA central nervous system,brain,glioma,gliosarcoma c.3140A>G p.H1047R 3:179234297-179234297 6
25 COSM22413 PDGFRA central nervous system,brain,glioma,gliosarcoma c.2472C>T p.V824V 4:54285873-54285873 6
26 COSM564 NRAS central nervous system,brain,glioma,gliosarcoma c.35G>A p.G12D 1:114716126-114716126 6
27 COSM41793 NF1 central nervous system,brain,glioma,gliosarcoma c.7765C>T p.Q2589* 17:31356986-31356986 6
28 COSM510736 NF1 central nervous system,brain,glioma,gliosarcoma c.7909C>T p.R2637* 17:31357308-31357308 6
29 COSM6920964 MSH6 central nervous system,brain,glioma,gliosarcoma c.3397A>G p.T1133A 2:47803644-47803644 6
30 COSM6954365 MED12 central nervous system,brain,glioma,gliosarcoma c.2345T>C p.L782P 23:71125469-71125469 6
31 COSM6978572 KDR central nervous system,brain,glioma,gliosarcoma c.2498G>A p.R833Q 4:55098148-55098148 6
32 COSM22932 FBXW7 central nervous system,brain,glioma,gliosarcoma c.1393C>T p.R465C 4:152328233-152328233 6
33 COSM6920966 FAT1 central nervous system,brain,glioma,gliosarcoma c.9056A>G p.N3019S 4:186617024-186617024 6
34 COSM6920965 FAT1 central nervous system,brain,glioma,gliosarcoma c.9056A>G p.N3019S 4:186617024-186617024 6
35 COSM6911771 EED central nervous system,brain,glioma,gliosarcoma c.455G>A p.W152* 11:86256415-86256415 6
36 COSM476 BRAF central nervous system,brain,glioma,gliosarcoma c.1799T>A p.V600E 7:140753336-140753336 6
37 COSM453 BRAF central nervous system,brain,glioma,gliosarcoma c.1397G>A p.G466E 7:140781611-140781611 6
38 COSM471 BRAF central nervous system,brain,glioma,gliosarcoma c.1790T>G p.L597R 7:140753345-140753345 6
39 COSM1587098 central nervous system,brain,glioma,gliosarcoma c.1399C>T p.R467* 13:48380062-48380062 6
40 COSM120005 central nervous system,brain,glioma,gliosarcoma c.742C>T p.R248W 17:7674221-7674221 6
41 COSM2744527 central nervous system,brain,glioma,gliosarcoma c.840A>T p.R280S 17:7673780-7673780 6
42 COSM6954366 central nervous system,brain,glioma,gliosarcoma c.2345T>C p.L782P 23:71125469-71125469 6
43 COSM3388181 central nervous system,brain,glioma,gliosarcoma c.764T>A p.I255N 17:7674199-7674199 6
44 COSM1382232 central nervous system,brain,glioma,gliosarcoma c.7909C>T p.R2637* 17:31357308-31357308 6
45 COSM308307 central nervous system,brain,glioma,gliosarcoma c.578A>G p.H193R 17:7674953-7674953 6
46 COSM1154293 central nervous system,brain,glioma,gliosarcoma c.1039C>T p.R347C 4:152328233-152328233 6
47 COSM2744526 central nervous system,brain,glioma,gliosarcoma c.840A>T p.R280S 17:7673780-7673780 6
48 COSM170725 central nervous system,brain,glioma,gliosarcoma c.1153C>T p.R385C 4:152328233-152328233 6
49 COSM6920967 central nervous system,brain,glioma,gliosarcoma c.7765C>T p.Q2589* 17:31356986-31356986 6
50 COSM94986 central nervous system,brain,glioma,gliosarcoma c.3140A>G p.H1047R 3:179234297-179234297 6
Sources

Expression for Gliosarcoma

About this section
Search GEO for disease gene expression data for Gliosarcoma.
Sources

Pathways for Gliosarcoma

About this section

Pathways related to Gliosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.86 CCND3 EGFR FGFR1 FGFR3 GFAP NFKBIA
2
Akt Signaling 64
Show member pathways
 13.4 CCND3 EGFR FGFR1 FGFR3 PIK3R2 PTEN
3
PAK Pathway 64
Show member pathways
 13.28 EGFR FGFR1 FGFR3 NFKBIA PIK3R2 PTEN
4
PI3K/AKT activation 66
Show member pathways
 13.1 EGFR FGFR1 FGFR3 PIK3R2 PTEN TP53
5
Phospholipase-C Pathway 64
Show member pathways
 13.04 EGFR FGFR1 FGFR3 PIK3R2 PTEN TP53
6
TNFR1 Pathway 64
Show member pathways
 12.94 CCND3 EGFR NFKBIA PIK3R2 PTEN TP53
7
PI3K-Akt signaling pathway 37
Show member pathways
 12.91 CCND3 EGFR FGFR1 FGFR3 PIK3R2 PTEN
8
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.83 EGFR FGFR1 FGFR3 NFKBIA PIK3R2 PTEN
9
Endometrial cancer 37
Show member pathways
 12.77 EGFR FGFR1 NFKBIA PIK3R2 PPARG PTEN
10
Gastric cancer 37
Show member pathways
 12.75 EGFR FGFR1 PIK3R2 PTEN TP53
11
Glioma 37
Show member pathways
 12.71 EGFR FGFR1 FGFR3 PIK3R2 PTEN TP53
12
NF-KappaB Family Pathway 64
Show member pathways
 12.67 EGFR FGFR1 FGFR3 NFKBIA PIK3R2
13
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.64 CCND3 EGFR NFKBIA PIK3R2 PTEN
14
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.59 EGFR FGFR1 FGFR3 NFKBIA PIK3R2 PTEN
15
MicroRNAs in cancer 37
12.47 EGFR FGFR3 PIK3R2 PTEN TP53
16
Development FGFR signaling pathway 22
Show member pathways
 12.43 FGFR1 FGFR3 NFKBIA PIK3R2
17
Human T-cell leukemia virus 1 infection 37
12.41 CCND3 NFKBIA PIK3R2 TP53
18
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.4 EGFR FGFR1 FGFR3 PIK3R2 PTEN TP53
19
RhoGDI Pathway 64
Show member pathways
 12.38 EGFR FGFR1 FGFR3 PIK3R2
20
Development IGF-1 receptor signaling 22
Show member pathways
 12.33 CCND3 NFKBIA PIK3R2 PTEN TP53
21
Apoptosis Pathway 72
Show member pathways
 12.33 EGFR FGFR1 FGFR3 NFKBIA PIK3R2 TP53
22
Pathways in cancer 37
12.33 CCND3 EGFR FGFR1 FGFR3 NFKBIA PIK3R2
23
Toll Comparative Pathway 64
Show member pathways
 12.29 FGFR1 NFKBIA PIK3R2 TP53
24
Epstein-Barr virus infection 37
12.27 CCND3 NFKBIA PIK3R2 TP53
25
Proteoglycans in cancer 37
12.27 EGFR FGFR1 PIK3R2 TP53
26
Viral carcinogenesis 37
12.27 CCND3 NFKBIA PIK3R2 TP53
27
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.24 NFKBIA PIK3R2 PPARG TP53
28
VEGF Signaling Pathway 61 67
Show member pathways
 12.2 EGFR FGFR1 FGFR3 PTEN
29
Cellular senescence (KEGG) 37
12.15 CCND3 PIK3R2 PTEN TP53
30
Integrated Breast Cancer Pathway 1
12.13 EGFR PIK3R2 PTEN TP53
31
Development EGFR signaling via small GTPases 22
Show member pathways
 12.1 EGFR NFKBIA PIK3R2 PTEN
32
Direct p53 effectors 1
12.03 EGFR PTEN SNAI2 TP53
33
Hepatitis C 37
12.02 EGFR NFKBIA PIK3R2 TP53
34
MAPK Pathway 72
Show member pathways
 11.98 EGFR NFKBIA PIK3R2 TP53
35
DNA Damage Response (only ATM dependent) 1
11.94 CCND3 PIK3R2 PTEN TP53
36
AKT Signaling Pathway 67
11.89 EGFR FGFR1 FGFR3 PIK3R2 PTEN TP53
37
Neural Crest Differentiation 1
11.88 FGFR1 FGFR3 GFAP SNAI2
38
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 11.88 CCND3 EGFR FGFR1 FGFR3 PIK3R2 PTEN
39
Androgen receptor signaling pathway 1
11.84 EGFR PIK3R2 PTEN
40
Small cell lung cancer 37
11.81 NFKBIA PIK3R2 PTEN TP53
41
Glioblastoma Multiforme 64
11.81 EGFR MGMT PIK3R2 PTEN TP53
42
Adherens junction 37
11.72 EGFR FGFR1 SNAI2
43
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.71 FGFR1 FGFR3 GFAP NES
44
Bladder cancer 37 1
11.66 EGFR FGFR3 PIK3R2 TP53
45
Alzheimers Disease Pathway 64
11.47 EGFR FGFR1 FGFR3
46
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.45 CCND3 NFKBIA TP53
47
Vemurafenib Pathway, Pharmacodynamics 61
11.42 EGFR FGFR1 FGFR3
48
G-protein signaling_Cross-talk between Ras-family GTPases 22
11.38 EGFR FGFR1 FGFR3 PIK3R2
49
Transcription_Transcription factor Tubby signaling pathways 22
11.3 EGFR PIK3R2 TP53
50
Aurora A signaling 1
11.11 NFKBIA TACC1 TACC3 TP53
Sources

GO Terms for Gliosarcoma

About this section

Cellular components related to Gliosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1

Biological processes related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 CCND3 EGFR FGFR1 FGFR3 PTEN
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 EGFR FGFR1 FGFR3 PTEN
3 cell proliferation GO:0008283 9.77 EGFR PTEN TACC1 TACC3 TP53
4 cellular response to insulin stimulus GO:0032869 9.73 PIK3R2 PPARG PTEN
5 regulation of cell proliferation GO:0042127 9.71 CCND3 EGFR FGFR1 NFKBIA
6 positive regulation of protein kinase B signaling GO:0051897 9.62 EGFR FGFR1 FGFR3 PIK3R2
7 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.61 FGFR1 FGFR3 PIK3R2
8 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.55 NFKBIA PPARG
9 white fat cell differentiation GO:0050872 9.54 PPARG SNAI2
10 negative regulation of telomerase activity GO:0051974 9.51 PPARG TP53
11 salivary gland morphogenesis GO:0007435 9.49 EGFR FGFR1
12 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.48 EGFR TP53
13 positive regulation of phospholipase activity GO:0010518 9.46 FGFR1 FGFR3
14 phosphatidylinositol phosphorylation GO:0046854 9.46 EGFR FGFR1 FGFR3 PIK3R2
15 cellular response to ionizing radiation GO:0071479 9.43 MGMT SNAI2 TP53
16 response to organic cyclic compound GO:0014070 9.35 EGFR IDH1 MGMT PPARG PTEN
17 negative regulation of apoptotic process GO:0043066 9.23 EGFR FGFR1 FGFR3 MGMT NFKBIA PTEN

Molecular functions related to Gliosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.77 EGFR NFKBIA PPARG PTEN TP53
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.58 EGFR FGFR1 FGFR3
3 protein phosphatase binding GO:0019903 9.46 EGFR PIK3R2 PPARG TP53
4 1-phosphatidylinositol-3-kinase activity GO:0016303 9.43 FGFR1 FGFR3 PIK3R2
5 fibroblast growth factor-activated receptor activity GO:0005007 9.32 FGFR1 FGFR3
6 identical protein binding GO:0042802 9.28 EGFR FGFR1 FGFR3 GFAP IDH1 NFKBIA
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGFR FGFR1 FGFR3 PIK3R2
Sources

Sources for Gliosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....